$VRPX News

Last published 1y ago

1y agoVRPXVirpax Pharmaceuticals Announces Reverse Stock SplitBusiness WireVirpax Pharmaceuticals, Inc. (NASDAQ:VRPX) ("Virpax" or the "Company") a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS)
1y agoVRPXVirpax Receives Positive Probudur™ Results for Dose Range Study Moves Towards Next Steps in INDBusiness WireVirpax Pharmaceuticals, Inc. (NASDAQ:VRPX) ("Virpax" or the "Company"), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS)
1y agoVRPXVirpax Looking to Use MET to Develop Intranasal COVID VaccineBusiness WireVirpax Pharmaceuticals, Inc. (NASDAQ:VRPX) ("Virpax" or the "Company"), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS)
1y agoVRPXVirpax's NES100 to be Presented at The Society of Toxicology by NCATSBusiness WireVirpax Pharmaceuticals, Inc. (NASDAQ:VRPX) ("Virpax" or the "Company"), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS)
1y agoVRPXVirpax Reports Positive Results in Human Study for its Molecular Envelope TechnologyBusiness WireVirpax Pharmaceuticals, Inc. (NASDAQ:VRPX) ("Virpax" or the "Company"), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS)
1y agoVRPXVirpax Confirms Positive Results with US Army with Probudur™ for Combat Care StudyBusiness WireVirpax Pharmaceuticals, Inc. (NASDAQ:VRPX) ("Virpax" or the "Company"), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS)
1y agoVRPXVirpax's Matthew Barnes to Present at Outsourcing in Clinical Trials ConferenceBusiness WireVirpax Pharmaceuticals, Inc. (NASDAQ:VRPX) ("Virpax" or the "Company"), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS)
1y agoVRPXSpartan Capital Securities Serves as Sole Placement Agent in Virpax Pharmaceuticals' $6 Million Follow-On OfferingGlobeNewswireNEW YORK, NY, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Spartan Capital Securities, LLC, a leading full-service investment banking and financial advisory firm, is proud to announce its role as sole placement agent for Virpax
1y agoVRPXVirpax Pharmaceuticals, Inc. Announces Closing of $6.0 Million Public Offering of Common Stock and Pre-Funded WarrantsBusiness WireVirpax Pharmaceuticals, Inc. (NASDAQ:VRPX) ("Virpax" or the "Company"), a preclinical-stage pharmaceutical company focused in novel and proprietary drug delivery systems across various pain indications, announced today
1y agoVRPXVirpax Pharmaceuticals, Inc. Announces Pricing of $6 Million Public Offering of Common Stock and Pre-Funded WarrantsBusiness WireVirpax Pharmaceuticals, Inc. (NASDAQ:VRPX) ("Virpax" or the "Company"), a preclinical-stage pharmaceutical company focused in novel and proprietary drug delivery systems across various pain indications, announced today
1y agoVRPXVirpax Announces Positive Results for the Swine Model Dose Range Finding Study for Probudur™Business WireVirpax Pharmaceuticals, Inc. (NASDAQ:VRPX) ("Virpax" or the "Company"), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS)
1y agoVRPXVirpax Announces Agreement with the U.S. Department of Health and Human Services for the Developmental Extension for NES100 Towards IND for Acute and Chronic Non-Cancer Pain AlternativeBusiness WireVirpax Pharmaceuticals, Inc. (NASDAQ:VRPX) ("Virpax" or the "Company"), a company specializing in developing pharmaceutical products for pain management, announced that it has been granted an extension of its
1y agoVRPXSpartan Capital Securities, LLC Serves as Sole Placement Agent in Virpax Pharmaceuticals, Inc.'s $5.0 Million Public OfferingGlobeNewswireNew York, NY, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Spartan Capital Securities, LLC, a leading investment banking firm, is pleased to announce its role as the sole placement agent in Virpax Pharmaceuticals, Inc.'s
1y agoVRPXVirpax Pharmaceuticals, Inc. Announces Closing of $5.0 Million Public Offering of Common Stock and Pre-Funded WarrantsBusiness WireVirpax Pharmaceuticals, Inc. (NASDAQ:VRPX) ("Virpax" or the "Company"), a preclinical-stage pharmaceutical company focused in novel and proprietary drug delivery systems across various pain indications, announced today
1y agoVRPXVirpax Pharmaceuticals, Inc. Announces Pricing of $5.0 Million Public Offering of Common Stock and Pre-Funded WarrantsBusiness WireVirpax Pharmaceuticals, Inc. (NASDAQ:VRPX) ("Virpax" or the "Company"), a preclinical-stage pharmaceutical company focused in novel and proprietary drug delivery systems across various pain indications, announced today
2y agoADIL VRPXAdial Pharmaceuticals Appoints Vinay Shah as Chief Financial OfficerGlobeNewswireGLEN ALLEN, Va., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and
2y agoVRPXVirpax Pharmaceuticals Reports 2024 Second Quarter Results and Recent DevelopmentsBusiness WireVirpax® Pharmaceuticals, Inc. ("Virpax" or the "Company") (NASDAQ:VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS)
2y agoVRPXVirpax Pharmaceuticals to Present at Sidoti Virtual Investor Conference August 14-15Business WireVirpax® Pharmaceuticals, Inc. ("Virpax" or the "Company") (NASDAQ:VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS)
2y agoVRPXVirpax Regains Compliance with Nasdaq Minimum Bid PriceBusiness WireVirpax® Pharmaceuticals, Inc. ("Virpax" or the "Company") (NASDAQ:VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS)
2y agoVRPXVirpax Announces Positive Results of Swine Model Pilot Study for Probudur™Business WireVirpax® Pharmaceuticals, Inc. ("Virpax" or the "Company") (NASDAQ:VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS)
2y agoVRPXVirpax Pharmaceuticals Secures $2.5 Million Loan Financing and an Agreement with an Institutional Investor to Negotiate Additional FundingBusiness Wire--Announces Reorganization of Board of Directors-- Virpax® Pharmaceuticals, Inc. ("Virpax" or the "Company") (NASDAQ:VRPX), a company specializing in developing non-addictive products for pain management,
2y agoVRPXVirpax® Pharmaceuticals to Present at 2024 BIO International ConventionBusiness WireVirpax® Pharmaceuticals, Inc. ("Virpax" or the "Company") (NASDAQ:VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS)
2y agoVRPXVirpax Announces Pricing of $2.25 Million Public OfferingBusiness WireVirpax® Pharmaceuticals, Inc. ("Virpax" or the "Company") (NASDAQ:VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS)
2y agoVRPXVirpax Pharmaceuticals Reports 2024 First Quarter Results and Recent DevelopmentsBusiness WireVirpax® Pharmaceuticals, Inc. ("Virpax" or the "Company") (NASDAQ:VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS)
2y agoVRPXVirpax Announces Results of Maximum Tolerated Dose Study for Probudur™Business Wire-Liposomal Formulation Developed to Provide Both Immediate and Sustained Pain Relief- Virpax® Pharmaceuticals, Inc. ("Virpax" or the "Company") (NASDAQ:VRPX), a company specializing in developing non-addictive
2y agoVRPXVirpax Pharmaceuticals Reports 2023 Year-End ResultsBusiness WireVirpax® Pharmaceuticals, Inc. ("Virpax" or the "Company") (NASDAQ:VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS)
2y agoVRPXVirpax Pharmaceuticals Announces Reverse Stock Split to Regain Compliance with Nasdaq's Minimum Bid PriceBusiness WireVirpax® Pharmaceuticals, Inc. ("Virpax" or the "Company") (NASDAQ:VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS)
2y agoVRPXVirpax Pharmaceuticals Announces Proposed Settlement of Litigation with Sorrento Therapeutics, Inc. and Scilex Pharmaceuticals, Inc.Business WireVirpax® Pharmaceuticals, Inc. ("Virpax" or the "Company") (NASDAQ:VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS)
2y agoVRPXVirpax Pharmaceuticals Announces Preliminary Results of ProbudurTM Pilot Study with the U.S. Army Institute of Surgical ResearchBusiness WireVirpax® Pharmaceuticals, Inc. ("Virpax" or the "Company") (NASDAQ:VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS)
2y agoVRPXVirpax Pharmaceuticals Announces Results of Special Shareholders MeetingBusiness WireVirpax® Pharmaceuticals, Inc. ("Virpax" or the "Company") (NASDAQ:VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS)
2y agoVRPXVirpax Pharmaceuticals Announces Notification from Nasdaq Related to Delayed Form 10-Q FilingBusiness WireVirpax® Pharmaceuticals, Inc. ("Virpax" or the "Company") (NASDAQ:VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS)
2y agoVRPXVirpax Pharmaceuticals Announces Leadership TransitionBusiness WireVirpax® Pharmaceuticals, Inc. ("Virpax" or the "Company") (NASDAQ:VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS)
2y agoVRPXVirpax Pharmaceuticals Reports 2023 Third Quarter Results and Recent DevelopmentsBusiness WireVirpax® Pharmaceuticals, Inc. ("Virpax" or the "Company") (NASDAQ:VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS)
3y agoVRPXVirpax Pharmaceuticals Announces that Envelta™ Remains on Track for Trial in Humans Following FDA ReviewBusiness WireVirpax® Pharmaceuticals, Inc. ("Virpax" or the "Company") (NASDAQ:VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS)
3y agoVRPXVirpax Pharmaceuticals Announces Extension of CRADA with the U.S. Army Institute of Surgical ResearchBusiness WireVirpax® Pharmaceuticals, Inc. ("Virpax" or the "Company") (NASDAQ:VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS)
3y agoVRPXGerald W. Bruce Appointed President and CEO of Novvae™ PharmaceuticalsBusiness WireVirpax® Pharmaceuticals, Inc. ("Virpax" or the "Company") (NASDAQ:VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS)
3y agoVRPXVirpax Pharmaceuticals Announces Results of Probudur™ Dose Escalation StudiesBusiness WireVirpax® Pharmaceuticals, Inc. ("Virpax" or the "Company") (NASDAQ:VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS)
3y agoVRPXVirpax Pharmaceuticals to Present at the LD Micro Main Event XVIBusiness Wire-- Presentation on Tuesday, October 3rd at 12 PM PT -- Virpax® Pharmaceuticals, Inc. ("Virpax" or the "Company") (NASDAQ:VRPX), a company specializing in developing non-addictive products for pain management,
3y agoVRPXAltasciences Chosen by Virpax to Support the Development of a New Drug to Prevent Spread of Flu-like VirusesBusiness WireAltasciences is pleased to have been chosen by Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) ("Virpax"), a company specializing in developing non-addictive products for pain management, PTSD, central nervous system (CNS)
3y agoVRPXVirpax Pharmaceuticals Announces the Formation of Novvae™ PharmaceuticalsBusiness Wire--Novvae to Focus Exclusively on OTC Product Candidates— --Clinical Trials for Virpax Rx Pipeline are Anticipated for 2024-- Virpax® Pharmaceuticals, Inc. ("Virpax" or the "Company") (NASDAQ:VRPX), a company
3y agoSCLX VRPXVirpax Pharmaceuticals Updates on LitigationBusiness WireVirpax® Pharmaceuticals, Inc. ("Virpax" or the "Company") (NASDAQ:VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS)
3y agoVRPXVirpax® Pharmaceuticals to Present at H.C. Wainwright 25th Annual Global Investment ConferenceBusiness WireVirpax® Pharmaceuticals, Inc. ("Virpax" or the "Company") (NASDAQ:VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS)
3y agoVRPXVirpax Pharmaceuticals Reports 2023 Second Quarter Results and Recent DevelopmentsBusiness WireVirpax® Pharmaceuticals, Inc. ("Virpax" or the "Company") (NASDAQ:VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS)
3y agoVRPXVirpax Pharmaceuticals Files Provisional Patent Application for NSAID Formulation and MethodBusiness WireVirpax® Pharmaceuticals, Inc. ("Virpax" or the "Company") (NASDAQ:VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS)
3y agoVRPXVirpax Pharmaceuticals, Inc. to Ring NASDAQ Closing Bell on July 24, 2023Business WireVirpax® Pharmaceuticals, Inc. ("Virpax" or the "Company") (NASDAQ:VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS)
3y agoVRPXVirpax Pharmaceuticals Files Provisional Patent Application for Intranasal DeliveryBusiness WireVirpax® Pharmaceuticals, Inc. ("Virpax" or the "Company") (NASDAQ:VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS)
3y agoVRPXVirpax Pharmaceuticals Enters into CRADA with the National Advisory Neurological Disorders and Stroke CouncilBusiness WireVirpax® Pharmaceuticals, Inc. ("Virpax" or the "Company") (NASDAQ:VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS)
3y agoVRPXVirpax Pharmaceuticals Announces CFO TransitionBusiness WireVirpax® Pharmaceuticals, Inc. ("Virpax" or the "Company") (NASDAQ:VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS)
3y agoVRPXVirpax Pharmaceuticals to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest on Tuesday, June 20th to Thursday, June 22nd at 9:00 A.M. ETBusiness WireVirpax® Pharmaceuticals, Inc. ("Virpax" or the "Company") (NASDAQ:VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS)
3y agoVRPXVirpax Pharmaceuticals Reports 2023 First Quarter Results and Recent DevelopmentsBusiness WireVirpax® Pharmaceuticals, Inc. ("Virpax" or the "Company") (NASDAQ:VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS)